# US 2021/0340528 A1 · Method for modifying target nucleic acid in genome of cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340528 A1
- Document ID: US20210340528A1
- Status: Published application
- Kind: A1
- Application number: 17/271,971
- Filed: 2019-08-30
- Published: 2021-11-04
- Earliest claimed: 2018-08-31
- Assignees: Industry-Academic Cooperation Foundation, Yonsei University
- Applicants: Industry-Academic Cooperation Foundation, Yonsei University
- Inventors: Hyong Bum KIM; Hui Kwon KIM
- Web page: https://patentgrep.com/patent/US20210340528A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are: a method for modifying a target nucleic acid in the genome of a cell using a novel PAM sequence; and a cell in which a target nucleic acid in the genome is modified thereby. Accordingly, genome editing can be performed by targeting a position that could not be previously targeted as a target for genome editing, and thus the range of applications of genome editing can be expanded.

## Claims

### Claim 1

A method for modifying a target nucleic acid in the genome of a cell, the method comprising:
incubating a cell comprising a target nucleic acid; a polynucleotide encoding a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) nuclease or a variant thereof; and a guide RNA,
wherein the target nucleic acid comprises a protospacer adjacent motif (PAM) and a target sequence complementary to the guide RNA,
the PAM consists of a sequence selected from the group consisting of 5′-NA-3′, 5′-NTG-3′, 5′-GTH-3′, 5′-VCGD-3′, 5′-TCGDG-3′, 5′-GGT-3′, 5′-BGC-3′, 5′-RTG-3′, 5′-NYGG-3′, 5′-AGCCA-3′, 5′-CTGCA-3′, 5′-TGTCA-3′, 5′-GCGCA-3′, 5′-GCGCT-3′, 5′-GCGTT-3′, 5′-AGCCC-3′, 5′-CGTCA-3′, 5′-GCGTA-3′, 5′-AGCCG-3′, 5′-GCGTC-3′, 5′-AGTCA-3′, 5′-AGCAC-3′, and 5′-AGCTC-3′,
the target nucleic acid can be recognized by a complex of the Cas nuclease or a variant thereof with the guide RNA, and
the complex of the Cas nuclease or a variant thereof with the guide RNA modifies the target nucleic acid sequence-specifically.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Cas nuclease is a nuclease derived from a bacterium selected from the group consisting of Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus aureus, Campylobacter jejuni, Legionella pneumophila, Neisseria meningitidis, Pasteurella multocida, Francisella novicida, and Prevotella disiens.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Cas nuclease is Cas9, Cpf1, C2c1, C2c2, C2c3, Cas3, Cas5, Cas7, Cas8, or Cas10.

### Claim 4 (depends on 1)

The method of claim 1, wherein the variant of the Cas nuclease is selected from the group consisting of xCas9, SpCas9-NG, Cas9 nickase, deactivated Cas9 (dCas9), and destabilized Cas9 (DD-Cas9).

### Claim 5 (depends on 1)

The method of claim 1, wherein when the variant of the Cas nuclease is SpCas9-NG, the PAM is a polynucleotide consisting of a nucleotide sequence selected from the group consisting of 5′-NA-3′, 5′-NTG-3′, 5′-GTH-3′, 5′-VCGD-3′, and 5′-TCGDG-3′.

### Claim 6 (depends on 1)

The method of claim 1, wherein when the Cas nuclease is Streptococcus pyogenes Cas9 (SpCas9), the PAM is a polynucleotide consisting of a nucleotide sequence selected from the group consisting of 5′-GGT-3′, 5′-BGC-3′, 5′-RTG-3′, 5′-NYGG-3′, 5′-AGCCA-3′, 5′-CTGCA-3′, 5′-TGTCA-3′, 5′-GCGCA-3′, 5′-GCGCT-3′, 5′-GCGTT-3′, 5′-AGCCC-3′, 5′-CGTCA-3′, 5′-GCGTA-3′, 5′-AGCCG-3′, 5′-GCGTC-3′, 5′-AGTCA-3′, 5′-AGCAC-3′, and 5′-AGCTC-3′.

### Claim 7 (depends on 1)

The method of claim 1, wherein the guide RNA is a polynucleotide complementary to a nucleotide sequence having consecutive 2 to 24 nucleotides in the 5′- or 3′-direction of the PAM in the target nucleic acid.

### Claim 8 (depends on 1)

The method of claim 1, wherein the length of the guide RNA is 17 to 24 nucleotides.

### Claim 9 (depends on 1)

The method of claim 1, wherein the modification is cleavage, insertion, cleavage, insertion, ligation, deamination, or combinations thereof.

### Claim 10 (depends on 1)

A cell in which a target nucleic acid in the genome is modified by the method of claim 1.
